newsfilter
← Latest News
PR Newswire·

CymaBay Therapeutics to Present New Data Highlighting Seladelpar's Unique Activity in Patients with Primary Biliary Cholangitis at The International Liver Congress™ 2023

Two abstracts focus on the unique mechanism of action of seladelpar; a third focuses on characterizing patient risk of PBC disease progression NEWARK, Calif., June 7, 2023 /PRNewswire/ -- CymaBay Therapeutics, Inc.